Foghorn Therapeutics Inc.’s FHTX share price has surged by 15.29%, which has investors questioning if this is right time to ...

Mavacamten is a first-in-class cardiac myosin ATPase inhibitor, approved by the United States Food and Drug Administration for the treatment of hypertrophic cardiomyopathy with obstructive physiology ...

After hours: February 3 at 4:10:51 PM EST Loading Chart for FHTX ...

1 Nashville VA Medical Center and the Departments of Surgery and Cell and Developmental Biology, Epithelial Biology Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA 2 ...